Skip to main content

CAR-T (Hematologic) Deal Benchmarks in Hematology

Median Upfront
$751M
Range: $389M - $1.1B
Total Deal Value
$3.8B
Range: $2.4B - $5.2B
Royalty Rate
9.2% - 17.2%
Tiered up to 21.2%
Dev Milestones
$639M
Range: $412M - $866M
Model Your Deal

Market Analysis

CAR-T (Hematologic) therapies in hematology have seen significant M&A and licensing activity in recent years. Based on analysis of 1,500+ verified transactions, the median upfront payment for a Phase 2 car-t (hematologic) asset in hematology is $751M, with total deal values reaching $3.8B. Development milestones average $639M, while regulatory milestones contribute $761M.

The hematology car-t (hematologic) landscape is characterized by high competitive intensity in lymphoma and myeloma with established treatment paradigms. Bispecific antibodies and next-generation cell therapies are displacing traditional chemotherapy combinations. The recommended deal structure allocates approximately 20% to upfront payments and 80% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for car-t (hematologic) hematology deals range from 9.2% to 17.2% at the base tier, with tiered escalation reaching 13.2%-21.2% on blockbuster sales. Commercial milestones averaging $1.6B further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a car-t (hematologic) hematology licensing deal?
Based on our analysis, Phase 2 car-t (hematologic) licensing deals in hematology average $751M in upfront payments, with a range of $389M to $1.1B depending on data quality, competitive positioning, and territorial scope.
What is the total deal value for car-t (hematologic) hematology transactions?
The median total deal value for Phase 2 car-t (hematologic) assets in hematology is $3.8B, ranging from $2.4B to $5.2B. This includes development milestones ($639M), regulatory milestones ($761M), and commercial milestones ($1.6B).
What royalty rates are standard for car-t (hematologic) deals in hematology?
Base royalty rates for car-t (hematologic) hematology transactions range from 9.2% to 17.2%, with tiered escalations reaching 13.2%-21.2% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.
How are milestones structured in car-t (hematologic) hematology deals?
CAR-T (Hematologic) hematology deals allocate approximately 80% of total deal value to milestones. Development milestones ($639M) make up the largest share, followed by commercial milestones ($1.6B) and regulatory milestones ($761M).
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Bispecific Antibody in Hematology

View

Trispecific Antibody in Hematology

View

CAR-T (Hematologic) in Oncology

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included